The decrease of dopamine D 2/D 3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB 1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D 2/D 3 antagonist [ 3H]raclopride and the novel CB 1 inverse agonis

Szabolcs Farkas, Katalin Nagy, Zhisheng Jia, Tibor Harkany, M. Palkóvits, Sean R. Donohou, Victor W. Pike, Christer Halldin, Domokos Máthé, L. Csiba, Balázs Gulyás

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Cannabinoid type-1 receptors (CB 1Rs) modulate synaptic neurotransmission by participating in retrograde signaling in the adult brain. Increasing evidence suggests that cannabinoids through CB 1Rs play an important role in the regulation of motor activities in the striatum. In the present study, we used human brain samples to examine the relationship between CB 1R and dopamine receptor density in case of Parkinson's disease (PD).Post mortem putamen, nucleus caudatus and medial frontal gyrus samples obtained from PD patients were used for CB 1R and dopamine D 2/D 3 receptor autoradiography. [ 125I]SD7015, a novel selective CB 1R inverse agonist, developed by a number of the present co-authors, and [ 3H]raclopride, a dopamine D 2/D 3 antagonist, were used as radioligands. Our results demonstrate unchanged CB 1R density in the putamen and nucleus caudatus of deceased PD patients, treated with levodopa (l-DOPA). At the same time dopamine D 2/D 3 receptors displayed significantly decreased density levels in case of PD putamen (control: 47.97±10.00fmol/g, PD: 3.73±0.07fmol/g (mean±SEM), p1R population even in late stages of levodopa treated PD. This further supports the presence of an intact CB 1R population which, in line with the conclusion of earlier publications, may be utilized as a pharmacological target in the treatment of PD. Furthermore we found discrepancy between a maintained CB 1R population and a decreased dopamine D 2/D 3 receptor population in PD striatum. The precise explanation of this conundrum requires further studies with simultaneous examination of the central cannabinoid and dopaminergic systems in PD using higher sample size.

Original languageEnglish
Pages (from-to)504-510
Number of pages7
JournalBrain Research Bulletin
Volume87
Issue number6
DOIs
Publication statusPublished - Apr 10 2012

Fingerprint

Raclopride
Cannabinoid Receptors
Caudate Nucleus
Putamen
Parkinson Disease
Dopamine
Cannabinoids
Levodopa
Population
Dopamine Receptors
Brain
Prefrontal Cortex
Autoradiography
Synaptic Transmission
Sample Size
Motor Activity
Pharmacology

Keywords

  • Dopamine D /D receptor
  • Endocannabinoid CB1 receptor
  • Human brain autoradiography
  • Molecular imaging biomarker
  • Parkinson's disease
  • Striatum

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The decrease of dopamine D 2/D 3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB 1 cannabinoid receptors in Parkinson's disease : A preliminary autoradiographic study with the selective dopamine D 2/D 3 antagonist [ 3H]raclopride and the novel CB 1 inverse agonis. / Farkas, Szabolcs; Nagy, Katalin; Jia, Zhisheng; Harkany, Tibor; Palkóvits, M.; Donohou, Sean R.; Pike, Victor W.; Halldin, Christer; Máthé, Domokos; Csiba, L.; Gulyás, Balázs.

In: Brain Research Bulletin, Vol. 87, No. 6, 10.04.2012, p. 504-510.

Research output: Contribution to journalArticle

@article{3c0725c7e79744179694b3879db16ffe,
title = "The decrease of dopamine D 2/D 3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB 1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D 2/D 3 antagonist [ 3H]raclopride and the novel CB 1 inverse agonis",
abstract = "Cannabinoid type-1 receptors (CB 1Rs) modulate synaptic neurotransmission by participating in retrograde signaling in the adult brain. Increasing evidence suggests that cannabinoids through CB 1Rs play an important role in the regulation of motor activities in the striatum. In the present study, we used human brain samples to examine the relationship between CB 1R and dopamine receptor density in case of Parkinson's disease (PD).Post mortem putamen, nucleus caudatus and medial frontal gyrus samples obtained from PD patients were used for CB 1R and dopamine D 2/D 3 receptor autoradiography. [ 125I]SD7015, a novel selective CB 1R inverse agonist, developed by a number of the present co-authors, and [ 3H]raclopride, a dopamine D 2/D 3 antagonist, were used as radioligands. Our results demonstrate unchanged CB 1R density in the putamen and nucleus caudatus of deceased PD patients, treated with levodopa (l-DOPA). At the same time dopamine D 2/D 3 receptors displayed significantly decreased density levels in case of PD putamen (control: 47.97±10.00fmol/g, PD: 3.73±0.07fmol/g (mean±SEM), p1R population even in late stages of levodopa treated PD. This further supports the presence of an intact CB 1R population which, in line with the conclusion of earlier publications, may be utilized as a pharmacological target in the treatment of PD. Furthermore we found discrepancy between a maintained CB 1R population and a decreased dopamine D 2/D 3 receptor population in PD striatum. The precise explanation of this conundrum requires further studies with simultaneous examination of the central cannabinoid and dopaminergic systems in PD using higher sample size.",
keywords = "Dopamine D /D receptor, Endocannabinoid CB1 receptor, Human brain autoradiography, Molecular imaging biomarker, Parkinson's disease, Striatum",
author = "Szabolcs Farkas and Katalin Nagy and Zhisheng Jia and Tibor Harkany and M. Palk{\'o}vits and Donohou, {Sean R.} and Pike, {Victor W.} and Christer Halldin and Domokos M{\'a}th{\'e} and L. Csiba and Bal{\'a}zs Guly{\'a}s",
year = "2012",
month = "4",
day = "10",
doi = "10.1016/j.brainresbull.2012.02.012",
language = "English",
volume = "87",
pages = "504--510",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - The decrease of dopamine D 2/D 3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB 1 cannabinoid receptors in Parkinson's disease

T2 - A preliminary autoradiographic study with the selective dopamine D 2/D 3 antagonist [ 3H]raclopride and the novel CB 1 inverse agonis

AU - Farkas, Szabolcs

AU - Nagy, Katalin

AU - Jia, Zhisheng

AU - Harkany, Tibor

AU - Palkóvits, M.

AU - Donohou, Sean R.

AU - Pike, Victor W.

AU - Halldin, Christer

AU - Máthé, Domokos

AU - Csiba, L.

AU - Gulyás, Balázs

PY - 2012/4/10

Y1 - 2012/4/10

N2 - Cannabinoid type-1 receptors (CB 1Rs) modulate synaptic neurotransmission by participating in retrograde signaling in the adult brain. Increasing evidence suggests that cannabinoids through CB 1Rs play an important role in the regulation of motor activities in the striatum. In the present study, we used human brain samples to examine the relationship between CB 1R and dopamine receptor density in case of Parkinson's disease (PD).Post mortem putamen, nucleus caudatus and medial frontal gyrus samples obtained from PD patients were used for CB 1R and dopamine D 2/D 3 receptor autoradiography. [ 125I]SD7015, a novel selective CB 1R inverse agonist, developed by a number of the present co-authors, and [ 3H]raclopride, a dopamine D 2/D 3 antagonist, were used as radioligands. Our results demonstrate unchanged CB 1R density in the putamen and nucleus caudatus of deceased PD patients, treated with levodopa (l-DOPA). At the same time dopamine D 2/D 3 receptors displayed significantly decreased density levels in case of PD putamen (control: 47.97±10.00fmol/g, PD: 3.73±0.07fmol/g (mean±SEM), p1R population even in late stages of levodopa treated PD. This further supports the presence of an intact CB 1R population which, in line with the conclusion of earlier publications, may be utilized as a pharmacological target in the treatment of PD. Furthermore we found discrepancy between a maintained CB 1R population and a decreased dopamine D 2/D 3 receptor population in PD striatum. The precise explanation of this conundrum requires further studies with simultaneous examination of the central cannabinoid and dopaminergic systems in PD using higher sample size.

AB - Cannabinoid type-1 receptors (CB 1Rs) modulate synaptic neurotransmission by participating in retrograde signaling in the adult brain. Increasing evidence suggests that cannabinoids through CB 1Rs play an important role in the regulation of motor activities in the striatum. In the present study, we used human brain samples to examine the relationship between CB 1R and dopamine receptor density in case of Parkinson's disease (PD).Post mortem putamen, nucleus caudatus and medial frontal gyrus samples obtained from PD patients were used for CB 1R and dopamine D 2/D 3 receptor autoradiography. [ 125I]SD7015, a novel selective CB 1R inverse agonist, developed by a number of the present co-authors, and [ 3H]raclopride, a dopamine D 2/D 3 antagonist, were used as radioligands. Our results demonstrate unchanged CB 1R density in the putamen and nucleus caudatus of deceased PD patients, treated with levodopa (l-DOPA). At the same time dopamine D 2/D 3 receptors displayed significantly decreased density levels in case of PD putamen (control: 47.97±10.00fmol/g, PD: 3.73±0.07fmol/g (mean±SEM), p1R population even in late stages of levodopa treated PD. This further supports the presence of an intact CB 1R population which, in line with the conclusion of earlier publications, may be utilized as a pharmacological target in the treatment of PD. Furthermore we found discrepancy between a maintained CB 1R population and a decreased dopamine D 2/D 3 receptor population in PD striatum. The precise explanation of this conundrum requires further studies with simultaneous examination of the central cannabinoid and dopaminergic systems in PD using higher sample size.

KW - Dopamine D /D receptor

KW - Endocannabinoid CB1 receptor

KW - Human brain autoradiography

KW - Molecular imaging biomarker

KW - Parkinson's disease

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=84859155879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859155879&partnerID=8YFLogxK

U2 - 10.1016/j.brainresbull.2012.02.012

DO - 10.1016/j.brainresbull.2012.02.012

M3 - Article

C2 - 22421165

AN - SCOPUS:84859155879

VL - 87

SP - 504

EP - 510

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 6

ER -